Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

CDK inhibitor AT7519

An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:cyclin-dependent kinase inhibitor AT7519M
Code name:AT7519
AT7519M
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search